<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Samarium Sm-153 lexidronam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Samarium Sm-153 lexidronam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Samarium Sm-153 lexidronam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="17080" href="/d/html/17080.html" rel="external">see "Samarium Sm-153 lexidronam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16565519"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Quadramet [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13185988"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F13186086"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose adjustments for extremes of weight have not been studied; use caution when determining dose for very thin or obese patients.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e770f735-88fd-49f6-89a6-6c590801d48d">Osteoblastic metastatic bone lesion pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoblastic metastatic bone lesion pain:</b> IV: 1 mCi/kg (37 MBq/kg)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991899"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-top:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution, patients with renal insufficiency may not tolerate the recommended hydration. </p></div>
<div class="block doha drugH1Div" id="F50989113"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, a need for dosage adjustment is unlikely since studies have not revealed hepatic excretion. </p></div>
<div class="block doe drugH1Div" id="F56586826"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F13186087"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: Hematologic: Thrombocytopenia (69%), leukopenia (59%), anemia (41%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Arrhythmias, hypertension, stroke</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Central nervous system: Dizziness</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Ecchymosis</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neuromuscular &amp; skeletal: Bone pain, spinal cord compression</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Renal: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Bronchitis, epistaxis</p></div>
<div class="block coi drugH1Div" id="F13186072"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to ethylenediaminetetramethylenephosphonic acid (EDTMP), similar phosphonate compounds, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F13186073"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: May cause myelosuppression (leukopenia, thrombocytopenia, and anemia). White blood cell and platelet nadir usually occur within 3 to 5 weeks, with recovery by 8 weeks; monitor blood counts for at least 8 weeks or until adequate marrow recovery. Consider current hematologic status and history of myelosuppressive response to other myelotoxic agents prior to therapy. Due to potential for additive hematologic toxicity, avoid concurrent chemotherapy and external beam radiation therapy unless benefits outweigh risks. </p>
<p style="text-indent:-2em;margin-left:4em;">• Bone pain flare: A transient increase in bone pain (usually mild) occurring within 3 days of administration has been reported in some patients; may be managed with analgesics. </p>
<p style="text-indent:-2em;margin-left:4em;">• Disseminated intravascular coagulation (DIC): Active DIC may be a risk factor for severe thrombocytopenia following therapy; deaths have occurred in patients with DIC receiving beta-emitting radiopharmaceuticals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with heart failure; recommended hydration to promote urinary excretion may be poorly tolerated and may require additional supportive management. </p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Use with caution in patients at risk for developing hypocalcemia (low calcium levels have been reported).  </p>
<p style="text-indent:-2em;margin-left:4em;">• Incontinence: Incontinent patients may require urinary catheterization to reduce the risk of radioactive contamination of clothes or bed linens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal insufficiency: Use with caution in patients with renal insufficiency; recommended hydration to promote urinary excretion may be poorly tolerated and may require additional supportive management.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Weight extremes: Dose adjustments for extremes of weight have not been studied; use caution when determining dose for very thin or obese patients.   </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Verify the radioactivity dose to be administered prior to administration. Patients should not be released until their radioactivity levels and exposure rates comply with federal and local regulations. Samarium Sm 153 lexidronam will not prevent and is not indicated for the treatment of spinal cord compression. </p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Vial stopper may contain latex.  </p></div>
<div class="block foc drugH1Div" id="F16565520"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Quadramet: 1850 MBq/mL (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F16565538"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322914"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Quadramet Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1850 mbq/ml (per each): $19,539.46</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F13204464"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer over 1 minute through a secure in-dwelling catheter, followed by a saline flush. Do not dilute or mix with other solutions. Give 500 mL of fluids (IV or orally) prior to administration. To minimize bladder exposure, patients should void as soon as possible  after injection. Precautions should be taken for 12 hours following administration. If possible, patients should urinate in a toilet (rather than a urinal); flush the toilet several times after each use. Promptly clean any spilled urine; if blood or urine is on clothing, wash separately or store for 1 to 2 weeks to allow for radioactive decay.</p>
<p style="text-indent:0em;margin-top:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal.</p></div>
<div class="block use drugH1Div" id="F13186071"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Osteoblastic metastatic bone lesion pain:</b> Relief of pain associated with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.</p></div>
<div class="block mst drugH1Div" id="F13255272"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block rep_considerations drugH1Div" id="F53623657"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Women of reproductive potential should have a negative pregnancy test prior to treatment and avoid becoming pregnant during or soon after treatment. Both males and females should use effective contraception following treatment.</p></div>
<div class="block pri drugH1Div" id="F13186080"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. All radiopharmaceuticals have the potential to cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F13186082"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if samarium Sm 153 lexidronam is excreted in breast milk; however, based on assumptions and calculations, the patient must be instructed to cease breastfeeding (US Nuclear Regulatory Commission 1977). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made to discontinue breastfeeding for administration of samarium sm 153 lexidronam; if samarium sm 153 lexidronam is administered, the manufacturer recommends substituting formula for breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F46313640"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelets weekly for at least 8 weeks (or until adequate marrow recovery); signs/symptoms of disseminated intravascular coagulation (DIC); signs/symptoms of hypocalcemia (in patients at risk for developing hypocalcemia); fluid status in patients with renal insufficiency or heart failure</p></div>
<div class="block pha drugH1Div" id="F46313633"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Samarium Sm-153 EDTMP has an affinity for bone and concentrates in areas of bone turnover in association with hydroxyapatite. Samarium Sm-153 EDTMP is taken up at the site of the bone metastases to deliver local radiation. In studies, samarium accumulated ~5 times more in osteoblastic lesions than in normal bone.</p></div>
<div class="block phk drugH1Div" id="F46313635"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Pain relief: 1 week; maximum pain relief occurs at 3 to 4 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (34.5% ± 15.5% in the first 6 hours)</p></div>
<div class="block phksp drugH1Div" id="F51159859"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Approximately one-third of Samarium Sm 153 EDTMP is excreted in the urine; clearance may be reduced in patients with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58208509"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Quadramet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Quadramet (Samarium SM 153 Lexidronam Injection) [prescribing information]. N. Billerica, MA: Lantheus Medical Imaging Inc; September 2017.</div>
</li>
<li>
<div class="reference">
                  US Nuclear Regulatory Commission. Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials. 1977.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16804 Version 81.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
